Recent Updates
Recently added Catalysts
AMRX Positive Sentiment

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Key Takeaway: Amneal Pharmaceuticals, Inc. will announce its third quarter 2026 financial results on November 3, 2026, before the market opens. The company will also host an audio webcast at 8:30 a.m. ET for investors. Amneal is recognized for its commitment to providing affordable and innovative medicines across various segments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amneal is set to report its third quarter results, indicating ongoing business activity.
  • The company continues to expand its portfolio with a focus on affordable medicines.
  • Amneal has a strong presence in the biopharmaceutical market with diverse offerings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+62%
120-day peak, hindsight
Typical move
3.5%
average across 12 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
KSHN001126
Phase 1 · Healthy Postmenopausal Women

Full Press Release Details

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code is 304152835. A replay of the webcast will be available shortly after the call.
About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit and follow us on LinkedIn.

Investor Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com

Frequently Asked Questions

When will Amneal report its Q3 2026 results?

Amneal will report its third quarter 2026 financial results on November 3, 2026.

What time is the Amneal Q3 2026 webcast?

The audio webcast for Amneal's Q3 2026 results will start at 8:30 a.m. ET.

How can I access the Amneal webcast?

The webcast can be accessed through the Investor Relations section of Amneal's website.

Who founded Amneal Pharmaceuticals?

Amneal was founded in 2002 by brothers Chirag and Chintu Patel.

Last updated: Oct 8, 2026